Stocksigma LogoStocksigma Logo

Symbiotec Pharmalab Reports Q1FY27 Financial Results with Strong Core API Performance

Symbiotec Pharmalab reported consolidated Q1FY27 revenue of Rs. 218.2 crs versus Rs. 203.2 crs in Q1FY26. Consolidated EBIDTA and PAT stood at Rs

Symbiotec Pharmalab Reports Q1FY27 Financial Results with Strong Core API Performance

Symbiotec Pharmalab Ltd 路 Press Release 路 22 Sept 2026, 1:20 am

Symbiotec Pharmalab Reports Q1FY27 Financial Results with Strong Core API Performance Symbiotec Pharmalab reported consolidated Q1FY27 revenue of Rs. 218.2 crs versus Rs. 203.2 crs in Q1FY26. Consolidated EBIDTA and PAT stood at Rs. 45.2 crs and Rs. 14.1 crs, impacted by Rs. 35 crs in operating expenses and depreciation from pre-revenue growth initiatives. Core API business grew 6% YoY to Rs. 215.3 crs, delivering ~30% EBIDTA margins. The company filed its first DCV ANDA in Sep'26, secured long-term CDMO contracts, and reduced net debt post-IPO to ~Rs. 326 crs as of 20th Sep'26.

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements